2.87
+0.07(+2.50%)
Currency In USD
| Previous Close | 2.8 |
| Open | 2.86 |
| Day High | 2.94 |
| Day Low | 2.59 |
| 52-Week High | 19.63 |
| 52-Week Low | 1.76 |
| Volume | 66,885 |
| Average Volume | 58,276 |
| Market Cap | 6.5M |
| PE | -0.28 |
| EPS | -10.36 |
| Moving Average 50 Days | 2.57 |
| Moving Average 200 Days | 5.05 |
| Change | 0.07 |
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 2:15 PM GMT
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
GlobeNewswire Inc.
Jan 05, 2026 2:15 PM GMT
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, t
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla.,